California Clinical Lab and Owner Pay $1.25M Over Alleged Illegal Marketer Kickbacks

A clinical laboratory based in Fountain Valley, California, along with its owner, has agreed to pay $1.25 million to settle allegations of healthcare fraud, federal officials announced on November 6, 2026. The settlement resolves allegations that the company paid illegal kickbacks to marketers to boost test referrals paid for by federal healthcare programs.

The agreement resolves a civil lawsuit brought under the False Claims Act in the U.S. District Court for the Eastern District of California. Prosecutors alleged that Lab Genomics LLC and its owner improperly paid third-party marketers based on the volume and value of the test referrals they generated.

Unlawful Marketing Commissions and Masked Invoices

According to federal prosecutors, the alleged conduct occurred between January 2020 and September 2022. During this period, the laboratory and its owner allegedly paid volume- and value-based commissions to three independent contractor marketers. These payments were designed to induce the marketers to recommend and arrange for healthcare providers to order laboratory tests from Lab Genomics.

The government alleged that the business and its owner knew these financial arrangements violated federal law. To hide the transactions, the parties allegedly structured invoices to make the commission payments look like fixed flat fees rather than per-referral compensation.

Understanding the Anti-Kickback Statute and Whistleblower Lawsuits

Under the federal Anti-Kickback Statute, offering or receiving financial incentives to generate medical referrals for services covered by programs like Medicare or Medicaid is strictly prohibited. The law is intended to protect patient care by ensuring that medical choices are based on patient health needs rather than financial incentives. Submitting claims generated through illegal kickbacks can also violate the False Claims Act.

This case originated as a whistleblower lawsuit filed by two individuals under the qui tam provisions of the False Claims Act. These provisions allow private parties to sue on behalf of the federal government and receive a share of any recovery. The whistleblowers in this action will receive $225,000 from the settlement proceeds. The government noted that it had previously resolved similar kickback allegations against Admera Health LLC and NEXT Bio-Research Services LLC.

What This Settlement Means for Patients and Healthcare Consumers

For ordinary patients, enforcement of kickback laws helps ensure that doctors order laboratory tests because they are medically necessary, not because a marketer or lab incentivized them. When improper financial arrangements drive healthcare decisions, taxpayer-funded programs like Medicare and Medicaid bear unnecessary costs, and public trust in medical testing can be damaged.

The government maintains a public reporting hotline at 1-800-HHS-TIPS (800-447-8477) for individuals who suspect potential healthcare fraud, waste, or abuse. The settlement contains no admission or finding of liability, as all resolved claims remain allegations only.

When to Consult an Attorney

If you work in healthcare, marketing, or medical billing and suspect your employer or business partner is engaging in unlawful referral arrangements, speaking with an attorney who understands healthcare fraud and whistleblower laws can help clarify your options under federal statute.

This article is general information based on U.S. Department of Justice and court or agency records available at publication time. It is not legal advice; laws and deadlines differ by state and by case. Published November 6, 2026.